Eli Lilly announced that J. Michael Cook will retire from the company's board of directors, effective April 20, 2009. Cook had been the director of the board since 2005. Michael Eskew has been appointed to replace Cook as chair of the audit committee. Eskew has been a member of Lilly's board since 2008, and served on both the audit and compensation committees.
Cerulean Pharma, a Cambridge, MA-based biopharma focused on nanoparticle-based drugs, announced the appointment of Oliver Fetzer as president and CEO. Fetzer was also elected to the company's board of directors, and will succeed Alan Crane, who has been named chairman of the board of directors. Fetzer was most recently SVP, corporate development and research development at Cubist Pharmaceuticals.